studies

la/mBC - HER2 positive - 2nd Line (L2), trastuzumab emtansine vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsDESTINY Breast03, 2022 (REV) 1.82 [1.18; 2.81] EMILIA, 2012 0.68 [0.55; 0.85] 1.09[0.42; 2.86]DESTINY Breast03, 2022 (REV), EMILIA, 2012294%991moderatenot evaluable deaths (OS) (extension)detailed resultsEMILIA, 2012 0.75 [0.64; 0.88] 0.75[0.64; 0.88]EMILIA, 201210%991NAnot evaluable progression or deaths (PFS)detailed resultsDESTINY Breast03, 2022 (REV) 3.57 [2.75; 4.63] EMILIA, 2012 0.65 [0.55; 0.77] 1.52[0.29; 8.07]DESTINY Breast03, 2022 (REV), EMILIA, 2012299%991moderatenot evaluable objective responses (ORR)detailed resultsEMILIA, 2012 1.73 [1.29; 2.32] 1.73[1.29; 2.32]EMILIA, 201210%786NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-06-28 02:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 317 - treatments: 1100

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons